Lymphoma
16 videos · last 6 months shuffled daily, then older videos newest first
▶
2:09 Roswell Park Opens New Trial for Rare Brain Lymphoma
Roswell Park is one of four sites in the United States and Europe offering a new clinical trial for patients with relapsed or refractory non-Hodgkin lymphoma in the central nervous system, led by Francisco Hernandez-Ilizaliturri, MD.
▶
8:32 MONVISO: Etentamig Safety in Relapsed Multiple Myeloma
Saurabh Chhabra, MBBS, MS, of Mayo Clinic Arizona discusses safety results from the phase 1b MONVISO study of etentamig, a BCMA x CD3 bispecific, in relapsed or refractory multiple myeloma, for Blood Cancers Today.
▶
4:10 Legend Biotech's Ying Huang on In Vivo CAR-T at EHA 2026
Dr. Ying Huang, CEO of Legend Biotech, discusses first Phase 1 results for LB2501, an investigational in vivo CAR-T therapy in relapsed or refractory B-cell non-Hodgkin lymphoma, presented at EHA 2026, in an OncoDaily interview sponsored by Legend Biotech.
▶
11:35 SOHO 2026 Highlights in Lymphoma, MDS and CLL
Jasmine M. Zain, MD, of Memorial Sloan Kettering, David Sallman, MD, of Moffitt Cancer Center, and Julie M. Vose, MD, of the University of Nebraska Medical Center discuss SOHO 2026 presentations, including phase 2a ofirnoflast results in lower-risk MDS.
▶
4:54 CELESTIAL-TNCLL-2: Sonrotoclax Plus Zanubrutinib in CLL
Mazyar Shadman, MD, MPH, of Fred Hutchinson Cancer Center tells Blood Cancers Today at ASCO 2026 about the phase 3 CELESTIAL-TNCLL-2 trial of sonrotoclax plus zanubrutinib versus venetoclax plus acalabrutinib in untreated CLL, which was recruiting at the time.
▶
11:32 Increased Dosing Interval of Mogamulizumab in Patients With CTCL
Christiane Querfeld, MD, PhD, of City of Hope on a trial that increased the dosing interval of mogamulizumab in patients with cutaneous T-cell lymphoma.
▶
6:55 LINKER-SMM1 Assesses Linvoseltamab for High-Risk Smoldering Multiple Myeloma
Paula Rodríguez-Otero, MD, PhD, of the University of Navarra, lead author of the phase 2 LINKER-SMM1 trial, discusses safety and efficacy results for linvoseltamab in high-risk smoldering multiple myeloma, including a May 2026 update, for Blood Cancers Today.
▶
1:53 BRUIN Study: Pirtobrutinib in R/R Follicular Lymphoma
Nirav Niranjan Shah, MD, of the Medical College of Wisconsin discusses results from the Phase I/II BRUIN study of pirtobrutinib in relapsed/refractory follicular lymphoma, including safety and disease stabilisation, at SOHO 2026.
▶
9:32 IRAKLIA: Isatuximab Results by Prior Anti-CD38 Therapy
Sikander Ailawadhi, MD, of the Mayo Clinic Comprehensive Cancer Center discusses a post hoc analysis of the phase 3 IRAKLIA trial of isatuximab with pomalidomide and dexamethasone by prior anti-CD38 therapy, presented at ASCO 2026, for Blood Cancers Today.
▶
7:44 CheckRare on MAVORIC Trial Results in Cutaneous T-Cell Lymphoma
H. Miles Prince, MD, of Peter MacCallum Cancer Centre compares results from the MAVORIC trial of mogamulizumab against vorinostat with outcomes recorded in an Australian cancer registry, in cutaneous T-cell lymphoma.
▶
4:52 A Young Hematologic Oncologist's Research Career
Luis Malpica Castillo, MD, of the Department of Lymphoma-Myeloma at The University of Texas MD Anderson Cancer Center, describes how his clinical research interests began in infectious disease and HTLV-1 and led him to lymphoma, for Blood Cancers Today.
▶
8:32 Drs. George Lenz and Loretta Nastoupil Discuss Phase 3 FRONTMIND Study
Dr. Loretta Nastoupil interviews Dr. Georg Lenz on the Phase 3 FRONTMIND study of tafasitamab plus lenalidomide and R-CHOP in first-line high-risk DLBCL, published in The Lancet in June 2026.
▶
8:17 Mogamulizumab in Danish Patients With CTCL
Lena Specht, MD, DMSc, of the University of Copenhagen on a Danish study of mogamulizumab in cutaneous T-cell lymphoma, approved in Europe in 2018 on the MAVORIC results.
▶
4:49 LB2501 In Vivo CAR-T: First-in-Human Data in B-Cell NHL
Ying Huang, PhD, former CEO of Legend Biotech, discusses first-in-human data for LB2501, an in vivo CD19/CD20 dual-targeting CAR-T lentiviral vector, in relapsed/refractory B-cell non-Hodgkin lymphoma at EHA 2026, for SOHO Insider.
▶
1:40 frontMIND: Tafasitamab Plus R-CHOP in High-Risk DLBCL
At ASCO 2026, Dr Georg Lenz discusses phase III frontMIND results with ecancer, in which tafasitamab plus lenalidomide and R-CHOP improved progression-free and event-free survival over R-CHOP alone in high-risk DLBCL and HGBL.
▶
2:05 UC Davis Clinical Trial Participant with Stage 4 Cancer Discusses Clinical Trials
A patient with follicular lymphoma, a form of cancer, has been on a clinical trial for eight years which is over 100 doses of immunotherapy.